Real-world Assessment of Patient Characteristics, Clinical Features, Treatment Patterns, and Outcomes Associated with Erythropoietic Protoporphyria and X-linked Protoporphyria Academic Background Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP) are two rare inherited metabolic disorders. The prevalence of EPP varies across coun...

Breakthrough Research on Micro-Scale Exploration of Thrombolysis Kinetics Research Background and Problem Venous thromboembolism (VTE), a severe health condition, causes approximately 500,000 deaths annually in the United States alone. The occurrence of VTE is closely related to the formation and resistance to dissolution of thrombi in veins, commo...

Targeting CD70 with iPSC-Derived CAR-NK Cell Therapy Background and Objectives of the Study Over the past decade, cellular therapy for cancer has revolutionized traditional treatment concepts by introducing the idea of a “living drug.” In particular, chimeric antigen receptor T cell (CAR-T) therapy has drastically improved the efficacy of immunothe...

Study on Three-Dimensional Monitoring of Red Blood Cell Sedimentation under External Magnetic Fields: A Novel Scientific Perspective Background and Research Objective With the widespread use of electronic devices in modern society, humans are increasingly exposed to external magnetic fields (MFs) in their living environments. However, the potential...

Combining Biological Aging and Genetic Susceptibility to Identify High-Risk Populations for Venous Thromboembolism Academic Background Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most fatal cardiovascular disease globally. The incidence of VTE is closely related to age, particularly i...

CM313 Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter Phase 1 Dose-Escalation and Expansion Trial Academic Background Multiple Myeloma (MM) is a common hematologic malignancy, accounting for approximately one-tenth of all hematologic malignancies. Although the use of immunomodulatory drugs ...